Introduction: Dual inhibition of SRC-and EGFR-dependent pathways may overcome
acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …

Abstract Background Bypass activation of Src family kinases can confer resistance to EGFR
tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the …

EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib)
develop acquired resistance, mediated by second-site EGFR T790M mutation in> 50% of …

EGFR mutations identify patients who are more likely to respond to treatment with epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than cytotoxic chemotherapy …

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have
shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating …

Objective The epithelial to mesenchymal transition (EMT) is associated with acquired
resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in …

Background: Gefitinib and erlotinib are used to treat advanced non-small cell lung cancer
(NSCLC). Gefitinib is a common first-line treatment, but most patients develop resistance …

7525^ Background: Despite initial responses to reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …